Traditional hemocompatibility assessment for extracorporeal circuits has historically relied on single-dimensional coagulation metrics, such as activated clotting time (ACT), prothrombin time (PT), and activated partial thromboplastin time (APTT) [17]. These standardized assays, primarily conducted under static or low-shear conditions as defined by ISO 10993 standards, are increasingly recognized as inadequate for predicting the clinical performance of advanced ECMO coatings. The fundamental limitation lies in their failure to replicate the complex hemodynamic environment characterized by extreme shear stress and high-velocity blood flow [18]. Static assays overlook the dynamic evolution of the protein-material interface and the subsequent cellular responses, particularly the rapid consumption of coagulation factors and the progressive activation of platelets and leukocytes. Consequently, there is a profound disconnect between successful laboratory results based on traditional clotting times and the persistent high incidence of thrombotic and hemorrhagic complications in clinical ECMO support [19].

The interaction between whole blood and the non-endothelialized synthetic surfaces triggers an aggressive thromboinflammatory response, characterized by the pathological remodeling of platelets and systemic inflammation [20]. Under extreme fluid shear stress, platelets undergo profound structural and functional alterations, notably including dense granule defects and the significant proteolytic shedding of Glycoprotein V (GPV) [21]. The loss of platelet receptors and the depletion of bioactive cargo within granules not only impair the primary hemostatic function but also facilitate the release of pro-inflammatory mediators. This mechanical and biochemical activation leads to the development of ECMO-associated acquired coagulopathy [22]. Simultaneously, the circuit interface initiates the complement cascade and activates innate immune pathways, resulting in systemic inflammatory response syndrome (SIRS) (Figure 1). The reciprocal amplification between thrombin generation and the release of inflammatory cytokines (e.g., IL-6, TNF-α) constitutes a vicious cycle of thromboinflammation, which exacerbates both circuit thrombosis and immune-mediated end-organ damage [23].

To break the thromboinflammatory cycle, next-generation ECMO coatings are shifting from passive antifouling to active modulation of the local immune microenvironment. Advanced surface engineering strategies focus on the simultaneous inhibition of the complement system and the specific guidance of macrophage polarization [24]. By incorporating biomimetic peptide networks or bioactive molecules capable of blocking the C3/C5 cascade, coatings can effectively suppress the recruitment and hyperactivation of leukocytes [25]. Furthermore, research has demonstrated that functionalized surfaces can drive macrophage polarization from a pro-inflammatory M1 phenotype toward a pro-healing M2 phenotype, thereby quelling the excessive inflammatory response triggered by the artificial interface. This transition from simple anticoagulation to comprehensive immune microenvironment remodeling represents a promising paradigm for enhancing the long-term safety and efficacy of extracorporeal life support devices [26].

In the extracorporeal circuit, the polyvinyl chloride (PVC) tubing serves as the primary conduit for prolonged, high-velocity blood flow, subjecting the luminal surface to continuous and extreme hydrodynamic shear stress [27]. In laboratory settings, many advanced hemocompatible coatings, such as physically adsorbed hydrogels or electrostatic layer-by-layer assemblies, demonstrate excellent antithrombotic properties under static or low-flow conditions. However, when applied to the luminal surface of long PVC tubing under physiological ECMO flow rates, these non-covalently bound coatings rapidly undergo mechanical degradation, delamination, and subsequent systemic embolization [28]. To address this interfacial instability, scalable engineering strategies must integrate robust anchoring mechanisms. Current translational research emphasizes covalent grafting techniques, bio-inspired polydopamine adhesive underlayers, and in situ photo-crosslinking. These approaches aim to establish an irreversible mechanical interlock between the compliant PVC substrate and the functional outer layer, ensuring long-term architectural integrity without shedding bioactive components during extended extracorporeal support [27].

The oxygenator module, predominantly constructed from polymethylpentene (PMP) hollow fiber membranes, presents a fundamentally different engineering paradigm. The primary physiological function of the PMP membrane is to facilitate highly efficient gas exchange (oxygenation and decarboxylation) through its complex microporous or asymmetric dense skin layer [29]. A critical paradox arises during the surface modification of these gas-permeable fibers: the incorporation of thick hydration layers, macromolecular hydrogels, or bulky peptide networks simultaneously introduces a substantial mass transfer resistance, despite significantly enhancing hemocompatibility [30]. This physical barrier severely attenuates the diffusion coefficients of oxygen and carbon dioxide, compromising the fundamental life-support capacity of the device. Consequently, the modification of oxygenator membranes requires a precise equilibrium. Engineering efforts must focus on achieving ultra-thin, conformal, and highly permeable nanocoatings. Techniques such as molecular-level surface functionalization, plasma-induced graft polymerization, or nanoscale biomimetic deposition are essential to construct an immune-modulatory interface without occluding the microscopic gas transport channels of the PMP fibers.

The transition from small-scale laboratory validation to clinical-scale manufacturing introduces profound challenges in quality control and coating consistency. Academic proof-of-concept studies typically evaluate novel biomaterials on two-dimensional flat sheets or short tubing segments with surface areas of only a few square centimeters. In contrast, a commercial adult ECMO oxygenator entails a complex three-dimensional topological architecture comprising thousands of tightly woven hollow fibers, yielding a total blood-contacting surface area of 1.5 to 2.5 square meters [31]. Achieving a homogenous, defect-free coating across this immense and intricately packed geometry represents a formidable industrial hurdle. Conventional liquid-phase immersion or spray coating methods frequently result in uneven thickness distribution, pooling at fiber intersections, and the capillary-driven bridging effect, which occludes the inter-fiber blood pathways and drastically increases fluidic resistance. Scaling up requires the development of advanced dynamic deposition technologies, such as continuous roll-to-roll processing for individual fibers prior to weaving, or precisely controlled chemical vapor deposition systems. These industrial strategies are mandatory to ensure absolute coating uniformity, eliminate stagnant flow zones, and guarantee the reproducible clinical efficacy of the modified macroscopic devices [28] [31].

Mandatory industrial sterilization techniques for medical devices, such as ethylene oxide exposure and gamma irradiation, pose a severe threat to the structural integrity of next-generation bioactive coatings [32]. For biomaterials aimed at clinical translation, achieving a sterility assurance level of 10⁻⁶ is a strict regulatory requirement. However, ethylene oxide sterilization frequently induces chemical alkylation of amino acid residues, irreversibly destroying the spatial conformation of biomimetic peptides and natural bioactive monomers. Similarly, gamma irradiation generates reactive oxygen species that trigger oxidative cleavage of polymer backbones and complete denaturation of incorporated biological factors [33]. Consequently, a profound engineering contradiction emerges in extracorporeal life support devices: the obligatory sterilization process essential for patient safety simultaneously eradicates the delicate immune-modulatory functions of the advanced interface, rendering many highly active laboratory coatings non-viable during clinical translation.

The incorporation of biological components with active modulatory functions, such as specific antibodies, functional peptides, or natural pharmacological monomers, into the extracorporeal circuit fundamentally alters the regulatory classification of the device. Under the regulatory frameworks of the US Food and Drug Administration and the China National Medical Products Administration, these advanced ECMO circuits are no longer considered standard Class III medical devices but are reclassified as highly regulated drug-device combination products [34]. This reclassification triggers a complex and time-consuming dual-track evaluation pathway, demanding not only stringent mechanical durability testing but also extensive pharmacological, pharmacokinetic, and toxicological validation [35]. The current absence of unified international guidelines specifically tailored for combination products modulating thromboinflammatory networks introduces significant regulatory uncertainty. This exponentially increases research costs and prolongs the clinical trial phase, thereby severely impeding the market access of novel coatings.

A core technical bottleneck in the translation of advanced ECMO coatings is the critical absence of standardized, multi-scale dynamic evaluation models. Current preclinical assessments often rely heavily on fragmented in vitro static standard tests (such as ISO 10993-based assays) or miniaturized microfluidic thrombosis-on-a-chip platforms. These systems fail to recapitulate the systemic thromboinflammatory cascade of a complete living organism under prolonged high-shear stress [36]. To bridge this translational gap, it is imperative to establish a hierarchical, multi-scale evaluation paradigm. This system must mandate sequential validation: initiating with ex vivo high-shear blood recirculation loops, progressing to small-animal arteriovenous bypass models to assess initial systemic immune responses, and culminating in large-animal long-term veno-arterial ECMO models [37]. Only through such comprehensive and continuous dynamic in vivo modeling can the true long-term hemocompatibility and end-organ protection efficacy of novel bio-interfaces be reliably determined prior to human clinical trials.